NPHLA Daily
NPHLA Daily
Wednesday, October 21, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 2 trial updates, 1 new study
NPHLA tracked 3 new official records on this desk today: 1 new study, 2 trial updates. First: New research in Diabetes, obesity & metabolism: “Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men”.
Metabolic signal
Trial status changed to “Recruiting”: PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A…
Phase 2, M.D. Anderson Cancer Center. Previously “Not yet recruiting”. Conditions: Sarcoma,Soft Tissue. Interventions: Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
Regulatory signal
What changed today in Regulatory: 1 proposed rule, 1 safety alert
NPHLA tracked 2 new official records on this desk today: 1 proposed rule, 1 safety alert. First: Proposed rule published: Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026.
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 trial update, 1 FDA announcement
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 FDA announcement. First: New trial registered: CIP-02-25 (Evaluation of MD60002 Device for Facial Skin Aging)
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 2 trial updates, 1 new study
- What changed today in Aesthetics & Longevity: 1 trial update, 1 FDA announcement
- What changed today in Regulatory: 1 proposed rule, 1 safety alert
- Class II recall: Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans… (U.S. Food and Drug Administration (Enforcement Report))
- Class II recall: SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland,… (U.S. Food and Drug Administration (Enforcement Report))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.